Publications from our Researchers

Several of our current PhD candidates and fellow researchers at the Data Science Institute have published, or in the proccess of publishing, papers to present their research.  

Citation

BibTex format

@article{Jolliffe:2020:10.1164/rccm.201909-1867OC,
author = {Jolliffe, DA and Stefanidis, C and Wang, Z and Kermani, NZ and Dimitrov, V and White, JH and McDonough, JE and Janssens, W and Pfeffer, P and Griffiths, CJ and Bush, A and Guo, Y and Christenson, S and Adcock, IM and Chung, KF and Thummel, KE and Martineau, AR},
doi = {10.1164/rccm.201909-1867OC},
journal = {Am J Respir Crit Care Med},
title = {Vitamin D Metabolism is Dysregulated in Asthma and Chronic Obstructive Pulmonary Disease.},
url = {http://dx.doi.org/10.1164/rccm.201909-1867OC},
year = {2020}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - RATIONALE: Vitamin D deficiency is common in patients with asthma and COPD. Low 25-hydroxyvitamin D (25[OH]D) levels may represent a cause or a consequence of these conditions. OBJECTIVE: To determine whether vitamin D metabolism is altered in asthma or COPD. METHODS: We conducted a longitudinal study in 186 adults to determine whether the 25(OH)D response to six oral doses of 3 mg vitamin D3, administered over one year, differed between those with asthma or COPD vs. controls. Serum concentrations of vitamin D3, 25(OH)D3 and 1α,25-dihydroxyvitamin D3 (1α,25[OH]2D3) were determined pre- and post-supplementation in 93 adults with asthma, COPD or neither condition, and metabolite-to-parent compound molar ratios were compared between groups to estimate hydroxylase activity. Additionally, we analyzed fourteen datasets to compare expression of 1α,25[OH]2D3-inducible gene expression signatures in clinical samples taken from adults with asthma or COPD vs. controls. MEASUREMENTS AND MAIN RESULTS: The mean post-supplementation 25(OH)D increase in participants with asthma (20.9 nmol/L) and COPD (21.5 nmol/L) was lower than in controls (39.8 nmol/L; P=0.001). Compared with controls, patients with asthma and COPD had lower molar ratios of 25(OH)D3-to-vitamin D3 and higher molar ratios of 1α,25(OH)2D3-to-25(OH)D3 both pre- and post-supplementation (P≤0.005). Inter-group differences in 1α,25[OH]2D3-inducible gene expression signatures were modest and variable where statistically significant. CONCLUSIONS: Attenuation of the 25(OH)D response to vitamin D supplementation in asthma and COPD associated with reduced molar ratios of 25(OH)D3-to-vitamin D3 and increased molar ratios of 1α,25(OH)2D3-to-25(OH)D3 in serum, suggesting that vitamin D metabolism is dysregulated in these conditions.
AU - Jolliffe,DA
AU - Stefanidis,C
AU - Wang,Z
AU - Kermani,NZ
AU - Dimitrov,V
AU - White,JH
AU - McDonough,JE
AU - Janssens,W
AU - Pfeffer,P
AU - Griffiths,CJ
AU - Bush,A
AU - Guo,Y
AU - Christenson,S
AU - Adcock,IM
AU - Chung,KF
AU - Thummel,KE
AU - Martineau,AR
DO - 10.1164/rccm.201909-1867OC
PY - 2020///
TI - Vitamin D Metabolism is Dysregulated in Asthma and Chronic Obstructive Pulmonary Disease.
T2 - Am J Respir Crit Care Med
UR - http://dx.doi.org/10.1164/rccm.201909-1867OC
UR - https://www.ncbi.nlm.nih.gov/pubmed/32186892
ER -